Loading clinical trials...

A Trial to Assess Diets Containing Beef vs. Poultry on Pancreatic Beta-Cell Function | Clinical Trials | Clareo Health

COMPLETEDNA

A Trial to Assess Diets Containing Beef vs. Poultry on Pancreatic Beta-Cell Function

A Randomized, Crossover Trial to Assess the Effects of Diets Containing Lean Beef vs. White Meat on Pancreatic Beta-cell Function in Men and Women With Prediabetes

NCT05456477•Midwest Center for Metabolic and Cardiovascular Research

View on ClinicalTrials.gov

Summary

The objective of this study is to assess and compare the effects of usual diets containing lean beef vs. lean poultry on pancreatic beta-cell responses in men and women with prediabetes.

Eligibility

Age

18 - 74 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Male or female 18 to 74 y of age, inclusive.
•2. Subject has a BMI of 25.0-39.9 kg/m2, inclusive.
•3. Subject has a Vein Access Scale score of 7-10.
•4. Subject has prediabetes as indicated by a fasting plasma glucose of 100-125 mg/dL and/or HbA1c of 5.7%-6.4% at screening.
•5. Subject is normally active and judged by the Investigator to be in general good health on the basis of medical history and screening measurements.
•6. Subject is willing to consume study-related foods and follow the dietary instructions during each 4-week treatment period.
•7. Subject is willing to come to the clinic for study food pick-up if needed.
•8. Subject is willing to follow his/her usual physical activity pattern throughout the study period.
•9. Subject agrees to avoid meat, poultry, seafood, and eggs, other than the study entrées, for the duration of the treatment periods.
•10. Subject has no plans to change smoking habits during the study period.
+4 more criteria

Exclusion Criteria

•1. Subject has a laboratory test result of clinical significance based on the judgment of the Principal Investigator or qualified designee.
•2. Subject has fasting blood glucose ≥ 126 mg/dL and/or HbA1c ≥ 6.5% at screening and/or known type 1 or type 2 diabetes mellitus.
•3. Subject has atherosclerotic cardiovascular disease including any of the following: clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease (symptomatic \[e.g., myocardial infarction, angina, transient ischemic attack, or stroke of carotid origin\] or \> 50% stenosis on angiography or ultrasound) or other forms of clinical atherosclerotic disease (e.g., renal artery disease).
•4. Subject has history or presence of a clinically significant health condition that, in the opinion of the Investigator, could interfere with the interpretation of the study results.
•5. Subject has a history of cancer in the prior 2 years, other than non-melanoma skin cancer or carcinoma in situ of the cervix.
•6. Subject has uncontrolled hypertension (systolic blood pressure ≥ 160 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg) at screening.
•7. Subject has unstable use (defined as initiation or change in dose) of anti-hypertensive medication or thyroid hormone replacement within 4 weeks of screening (Appendix 1).
•8. Subject has used alpha- or beta-adrenergic blockers and/or high-dose (\> 25 mg/d) thiazide diuretics within 4 weeks of screening (Appendix 1).
•9. Subject has used diabetes medications including any alpha-glucosidase inhibitor, biguanide (metformin), thiazolidinedione, dipeptidyl peptidase-4 inhibitor, meglitinide, sulfonylurea, Sodium-glucose Cotransporter-2 inhibitor, or GLP-1 receptor agonist within 4 weeks of screening (Appendix 1).
•10. Subject has used systemic corticosteroids within 4 weeks of screening (Appendix 1).
+12 more criteria

Locations (1)

Illinois Institute of Technology

Chicago, Illinois, United States

Key Dates

Start Date

October 7, 2022

Primary Completion Date

September 22, 2023

Completion Date

September 22, 2023

Last Updated

October 18, 2023

Enrollment

ACTUAL participants

Conditions

PreDiabetes

Interventions

Beef

OTHER

Poultry

OTHER

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

NCT05119179

PreDiabetes

View study

RECRUITINGNA

Rural Alliance for Diabetes Prevention

NCT06252038

PreDiabetes

View study

RECRUITINGNA

WatchWell: Simple and Practical Strategies to Reduce the Negative Health Impact of Sedentary Screen Time

NCT06963736

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 18, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Trial to Assess Diets Containing Beef vs. Poultry on Pancreatic Beta-Cell Function

Inclusion Criteria

Exclusion Criteria

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

Rural Alliance for Diabetes Prevention

WatchWell: Simple and Practical Strategies to Reduce the Negative Health Impact of Sedentary Screen Time

Human Immunodeficiency Virus (HIV) Food Insecurities

Development of an Inclusive Adaptive Treatment Strategy for Weight Loss in People With Prediabetes Using a Sequential Multiple Assignment Randomized Trial

Cleaner Air for Lower Cardiometabolic Risk